A Commentary on Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Human Genetics

• Publication date

  2012-12-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/jhg.2012.142PMID 23223009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families

  2012cited by this paper
• Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.

  2011cited by this paper
• Single‐nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish‐Ashkenazi descent

  2010cited by this paper
• Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women

  2009cited by this paper
• Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high‐risk non BRCA1/2 French Canadian breast and ovarian cancer families

  2008cited by this paper
• The emerging landscape of breast cancer susceptibility

  2007cited by this paper
• Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses

  2006cited by this paper
• Mutational analysis of the BRCA1‐interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2‐negative probands from breast‐ovarian cancer families and among early‐onset breast cancer cases and reference individuals

  2003cited by this paper
• Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1.

  2000cited by this paper

• Correlation between ZBRK1/ZNF350 gene polymorphism and breast cancer

  2021cites this paper
• A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen

  2016cites this paper
• Functional SNP in 3′‐UTR MicroRNA‐Binding Site of ZNF350 Confers Risk for Age‐Related Cataract

  2016cites this paper
• Long‐Read Single Molecule Real‐Time Full Gene Sequencing of Cytochrome P450‐2D6

  2016cites this paper
• In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.

  2015cites this paper
• Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.

  2015cites this paper
• Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer

  2014cites this paper